EHA: Hi, It was great to meet with Aussie Neil... - CLL Support

CLL Support

22,456 members38,596 posts

EHA

bkoffman profile image
bkoffmanCLL CURE Hero
1 Reply

Hi,

It was great to meet with Aussie Neil and many other CLL advocates in Amsterdam for EHA where I lectured to an overflow room on CAR-T and also as part of a panel on MRD in a satellite event.

In Europe, advocates are much more involved with professional organizations and government payers compared to the USA.

There is an advocacy track at EHA and that is where I spoke, but there were many hematologists in the room as well as other advocates, patients, payers, and industry.

Some surprisingly good results were presented and will report on them soon with some interesting interviews. The field is moving so fast that trials set up a few years ago are answering questions that may no longer be relevant. I will post more on my musing on this soon- still trying to catch up on my interviews from ASH.

Time is a jet plane, and sometimes I feel like one too

Stay strong

Brian CLLSociety.org -from the Amsterdam Airport

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
1 Reply
AussieNeil profile image
AussieNeilAdministrator

Great to meet with you too Brian. Safe travels almost home to you and your wife, before you head back over the pond once again. I've summarised the MRD-Undetectable satellite meeting here: healthunlocked.com/cllsuppo...

but with the rest of our community, I will look forward to your EHA reports.

Great that we are all in this together,

Neil

You may also like...

News about V+O and Acalabrutinib from EHA

duration treatments of non-chemo drugs. In this interview from EHA 2019, Dr. Peter Hillman...

My good news and more research news from EHA and iwCLL

related to our co-morbidities:...

EHA 2019: Dr. Maloney on CAR-T and Dr. Davids of Chemo-Immunotherapy combinations

from our conversation at EHA in Amsterdam. See:...

EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor

https://cllsociety.org/2022/08/eha-2022-outcomes-following-treatment-with-a-covalent-btk-and-bcl2-in

Expert Perspective on Key Trial Updates in Treatment of CLL: What You Need to Know From ASCO/EHA/ICML 2021

Oncology (ASCO), European Hematology Association (EHA), and International Conference on Malignant...